Factors Affecting Pharmacokinetic Variability of Imatinib Mesylate (Gleevec, STI-571)
Imatinib mesylate, the first tyrosine kinase inhibitor to gain approval by the FDA, remains as a pivotal example of rational drug design. Initially, imatinib was found to target the bcr-abl fusion protein in CML and further targets have subsequently been identified, including c-kit in GIST. Though a great number of studies have elucidated underlying mechanisms to explain emerging resistance to this anti-cancer agent, many cases of resistance remain unexplained. Furthermore, patients exhibit high interindividual variability in imatinib pharmacokinetics, which may contribute to suboptimal drug exposure and response.
|Publisher||Erasmus MC: University Medical Center Rotterdam|
|Promotor||Verweij, J. (Jaap)|
|Sponsor||Verweij, Prof. Dr. J. (promotor)|
|Keywords||chronic myelogenous leukemia, imatinib mesylate|
Gardner, E.R.. (2008, April 18). Factors Affecting Pharmacokinetic Variability of Imatinib Mesylate (Gleevec, STI-571). Erasmus MC: University Medical Center Rotterdam. Retrieved from http://hdl.handle.net/1765/12226